Premium
The treatment of 45 patients with cutaneous T‐cell lymphoma with low doses of interferon‐α2a and etretinate
Author(s) -
DRÉNO B.,
CLAUDY A.,
MEYNADIER J.,
VERRET J.L.,
SOUTEYRAND P.,
ORTONNE J.P.,
KALIS B.,
GODEFROY W.Y.,
BEERBLOCK K.,
THILL L.
Publication year - 1991
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1991.tb14772.x
Subject(s) - etretinate , mycosis fungoides , medicine , alpha interferon , interferon alfa , cutaneous t cell lymphoma , interferon , gastroenterology , alpha (finance) , lymphoma , dermatology , immunology , surgery , psoriasis , construct validity , patient satisfaction
Summary Forty‐five patients with cutaneous T‐cell lymphomas (CTCL), 32 with mycosis fungoides (MF) and 13 with Sézary syndrome (SS), were treated with interferon‐α2a (IFN‐α2a) (6–9 ± 10IU daily) for 3 months. Those responding to treatment were then treated with interferon‐α alone (6–9 ± 10 6 IU three times weekly), and non‐responders received a combination of etretinate(0·5 mg/kg/day) and IFN‐α2a in similar concentrations. After 12 months of treatment, 28/ 45 patients (62–2%) were in complete or partial (>50%) remission. Of these. 17 (60±7%) were receiving IFN‐α alone and II the combined interferon–retinoid therapy. Of the patients with MF stage I and II,20/25 were responders (12 receiving IFN‐α alone and eight on combined therapy), whereas only 8/20 with Stage IV or SS responded to treatment (five receiving IFN‐α2a alone and three combined therapy). These results suggest that the association of etretinate with low‐dose recombinant IFN‐α2a is an effective means of treating epidermotropic CTCL, particularly in the early stages.